FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783604615> ?p ?o ?g. }

• W2783604615 endingPage "470" @default.
• W2783604615 startingPage "462" @default.
• W2783604615 abstract "Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant PI3K-α/δ activity that has demonstrated clinical activity and manageable safety when administered as monotherapy in a phase II study. Combination therapy may overcome compensatory signalling that could occur with PI3K pathway inhibition, resulting in enhanced inhibitory activity, and preclinical studies of copanlisib with gemcitabine have demonstrated potent anti-tumour activity in vivo. A phase I, open-label, dose-escalation study to evaluate the safety, tolerability and recommended phase II dose (RP2D) of copanlisib with gemcitabine or with cisplatin plus gemcitabine (CisGem) in patients with advanced malignancies, including an expansion cohort in patients with biliary tract cancer (BTC) at the RP2D of copanlisib plus CisGem. Copanlisib and gemcitabine were administered on days 1, 8 and 15 of a 28-day cycle; maximum tolerated dose (MTD) and RP2D of copanlisib were determined. Copanlisib plus CisGem was administered on days 1 and 8 of a 21-day cycle; pharmacokinetics and biomarkers were assessed. Fifty patients received treatment as follows: dose-escalation cohorts, n=16; copanlisib plus CisGem cohort, n=14; and BTC expansion cohort, n=20. Copanlisib 0.8 mg kg−1 plus gemcitabine was the MTD and RP2D for both combinations. Common treatment-emergent adverse events included nausea (86%), hyperglycaemia (80%) and decreased platelet count (80%). Copanlisib exposure displayed a dose-proportional increase. No differences were observed upon co-administration of CisGem. Response rates were as follows: copanlisib plus gemcitabine, 6.3% (one partial response in a patient with peritoneal carcinoma); copanlisib plus CisGem, 12% (one complete response and three partial responses all in patients with BTC (response rate 17.4% in patients with BTC)). Mutations were detected in PIK3CA (1 out of 43), KRAS (10 out of 43) and BRAF (2 out of 22), with phosphate and tensin homologue protein loss in 41% (12 out of 29). Copanlisib plus CisGem demonstrated a manageable safety profile, favourable pharmacokinetics, and potentially promising clinical response." @default.
• W2783604615 created "2018-01-26" @default.
• W2783604615 creator A5003580192 @default.
• W2783604615 creator A5003626165 @default.
• W2783604615 creator A5019214686 @default.
• W2783604615 creator A5031338691 @default.
• W2783604615 creator A5058205506 @default.
• W2783604615 creator A5059915005 @default.
• W2783604615 creator A5063651822 @default.
• W2783604615 creator A5067111908 @default.
• W2783604615 date "2018-01-18" @default.
• W2783604615 modified "2023-10-17" @default.
• W2783604615 title "Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer" @default.
• W2783604615 cites W1771453957 @default.
• W2783604615 cites W1967291435 @default.
• W2783604615 cites W1991472738 @default.
• W2783604615 cites W2012733679 @default.
• W2783604615 cites W2115261608 @default.
• W2783604615 cites W2133575075 @default.
• W2783604615 cites W2138526882 @default.
• W2783604615 cites W2146414563 @default.
• W2783604615 cites W2161437969 @default.
• W2783604615 cites W2169450835 @default.
• W2783604615 cites W2174398469 @default.
• W2783604615 cites W2296095373 @default.
• W2783604615 cites W2315340994 @default.
• W2783604615 cites W2427979215 @default.
• W2783604615 cites W2520639290 @default.
• W2783604615 cites W2525724642 @default.
• W2783604615 cites W2527775548 @default.
• W2783604615 cites W2557672556 @default.
• W2783604615 cites W2729141564 @default.
• W2783604615 cites W2762226752 @default.
• W2783604615 cites W3144288344 @default.
• W2783604615 cites W4292655696 @default.
• W2783604615 doi "https://doi.org/10.1038/bjc.2017.428" @default.
• W2783604615 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5830590" @default.
• W2783604615 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29348486" @default.
• W2783604615 hasPublicationYear "2018" @default.
• W2783604615 type Work @default.
• W2783604615 sameAs 2783604615 @default.
• W2783604615 citedByCount "31" @default.
• W2783604615 countsByYear W27836046152018 @default.
• W2783604615 countsByYear W27836046152019 @default.
• W2783604615 countsByYear W27836046152020 @default.
• W2783604615 countsByYear W27836046152021 @default.
• W2783604615 countsByYear W27836046152022 @default.
• W2783604615 countsByYear W27836046152023 @default.
• W2783604615 crossrefType "journal-article" @default.
• W2783604615 hasAuthorship W2783604615A5003580192 @default.
• W2783604615 hasAuthorship W2783604615A5003626165 @default.
• W2783604615 hasAuthorship W2783604615A5019214686 @default.
• W2783604615 hasAuthorship W2783604615A5031338691 @default.
• W2783604615 hasAuthorship W2783604615A5058205506 @default.
• W2783604615 hasAuthorship W2783604615A5059915005 @default.
• W2783604615 hasAuthorship W2783604615A5063651822 @default.
• W2783604615 hasAuthorship W2783604615A5067111908 @default.
• W2783604615 hasBestOaLocation W27836046151 @default.
• W2783604615 hasConcept C121608353 @default.
• W2783604615 hasConcept C126322002 @default.
• W2783604615 hasConcept C143998085 @default.
• W2783604615 hasConcept C197934379 @default.
• W2783604615 hasConcept C2776694085 @default.
• W2783604615 hasConcept C2778375690 @default.
• W2783604615 hasConcept C2780258809 @default.
• W2783604615 hasConcept C2780580376 @default.
• W2783604615 hasConcept C31760486 @default.
• W2783604615 hasConcept C71924100 @default.
• W2783604615 hasConcept C90924648 @default.
• W2783604615 hasConcept C98274493 @default.
• W2783604615 hasConceptScore W2783604615C121608353 @default.
• W2783604615 hasConceptScore W2783604615C126322002 @default.
• W2783604615 hasConceptScore W2783604615C143998085 @default.
• W2783604615 hasConceptScore W2783604615C197934379 @default.
• W2783604615 hasConceptScore W2783604615C2776694085 @default.
• W2783604615 hasConceptScore W2783604615C2778375690 @default.
• W2783604615 hasConceptScore W2783604615C2780258809 @default.
• W2783604615 hasConceptScore W2783604615C2780580376 @default.
• W2783604615 hasConceptScore W2783604615C31760486 @default.
• W2783604615 hasConceptScore W2783604615C71924100 @default.
• W2783604615 hasConceptScore W2783604615C90924648 @default.
• W2783604615 hasConceptScore W2783604615C98274493 @default.
• W2783604615 hasIssue "4" @default.
• W2783604615 hasLocation W27836046151 @default.
• W2783604615 hasLocation W27836046152 @default.
• W2783604615 hasLocation W27836046153 @default.
• W2783604615 hasLocation W27836046154 @default.
• W2783604615 hasOpenAccess W2783604615 @default.
• W2783604615 hasPrimaryLocation W27836046151 @default.
• W2783604615 hasRelatedWork W1977727607 @default.
• W2783604615 hasRelatedWork W2011851765 @default.
• W2783604615 hasRelatedWork W2033082527 @default.
• W2783604615 hasRelatedWork W2087016115 @default.
• W2783604615 hasRelatedWork W2118940674 @default.
• W2783604615 hasRelatedWork W2135497551 @default.
• W2783604615 hasRelatedWork W2167571882 @default.
• W2783604615 hasRelatedWork W2349164817 @default.
• W2783604615 hasRelatedWork W2371186119 @default.

• next